Invega Sustenna 50 mg

Invega Sustenna 50 mg is an extended-release suspension of palperidone palmitate for intramuscular use. It is commonly used in the management of schizophrenia. This medication is designed to provide long-lasting effects with periodic injections.

Invega Sustenna 50 mg is primarily used for the treatment of schizophrenia in adults. This medication is part of a long-acting injectable therapy, which may help maintain consistent levels of the active ingredient in the body. It is often prescribed for individuals who have difficulty adhering to daily oral medication regimens. The extended-release formulation is intended to simplify treatment and improve compliance.

Common effects of Invega Sustenna 50 mg may include injection site reactions, such as pain, swelling, or redness. Some individuals may experience weight gain, restlessness, or drowsiness. It is important to discuss any persistent or severe side effects with a healthcare provider.

Invega Sustenna 50 mg should be administered by a healthcare professional experienced in intramuscular injections. It is essential to follow the prescribed dosage and schedule. Patients should be monitored for any signs of allergic reactions or other adverse effects. This medication may cause dizziness or drowsiness, so caution is advised when operating machinery or driving.

Invega Sustenna 50 mg may interact with other medications, including those that affect the central nervous system, such as sedatives or antidepressants. Alcohol consumption should be avoided as it can enhance the sedative effects. It is important to inform your healthcare provider about all medications, supplements, and herbal products you are taking to avoid potential interactions.